E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients with moderate persistent bronchial asthma and homozygous for arginine at the 16th position of the beta-2-adrenergic receptor |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 6.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10003553 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To compare the efficacy and safety of tiotropium inhalation solution 5 mcg 2 puffs of 2.5 mcg once daily delivered by the Respimat inhaler with that of salmeterol HFA MDI 50 mcg 2 puffs of 25 mcg twice daily in moderate persistent asthmatic patients homozygous for B16-Arg/Arg. |
|
E.2.2 | Secondary objectives of the trial |
Efficacy -Daily morning and evening peak expiratory flow pre-dose, weekly means -Peak expiratory flow variability the difference between the highest morning PEF value and the highest evening PEF value of one day divided by the arithmetic mean of these two PEF values, weekly means -Daily morning and evening FEV1 pre-dose, weekly means -Daily diary on asthma control questionnaire on asthma symptoms and use of as needed rescue medication -Morning pre-dose FEV1 and morning pre-dose FVC on study visits -Mini-Asthma Quality of Life Questionnaire Mini AQLQ on study visits -Number of patients with at least one exacerbation of asthma Safety -Vital signs pulse, blood pressure on study visits -Laboratory investigations at visit 1 -Physical examination and 12-lead ECG at visit 1 and end of study -Adverse events |
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
1.Patients must be homozygous for arginine at the 16th amino acid position of the beta2 adrenergic receptor B16 Arg/Arg . 2.All patients must sign and date an Informed Consent Form for the study consistent with ICH-GCP guidelines and local legislation prior to participation in the trial 3.Male or female outpatients with at least 18 years of age, but not older than 60 years 4.Patients must have a documented history of asthma 5.Patients must be current non-smokers or ex-smokers with a cigarette smoking history of 10 pack-years and smoking cessation at least one year prior to study enrolment 6.All patients must be on a maintenance treatment with inhaled corticosteroids alone or in a fixed combination with a LABA or a SABA with a total daily dose of 400 - 1000 mcg budesonide or equivalent within the last 3 months and with a stable dose within the last 3 weeks prior to visit 1 7.Two groups of patients are eligible for this study depending on their LABA pre-treatment Patients who are on a maintenance treatment with LABAs with a total daily dose of at least 100 mcg salmeterol or at least 18 mcg formoterol within the last 3 months and a stable dose within the last 3 weeks prior to visit 1 are eligible if they meet the following spirometric criterion Pre-bronchodilator FEV1 90 of predicted normal at visit 1 Patients who have not been treated with LABAs within the last year before visit 1 are eligible if they meet the following spirometric criterion Pre-bronchodilator FEV1 80 of predicted normal at visit 1 Predicted normal values will be calculated according to ECSC 8.Reversibility of airways obstruction must be demonstrated by a reversibility test with ipratropium and salbutamol at visit 1. Patients inhale 4 puffs 80 mcg ipratropium from the MDI, PFT by spirometry is performed pre-dose first PFT and 45 minutes after ipratropium administration second PFT , then patients inhale 4 puffs 400 mcg from the salbutamol MDI and PFT is performed again 30 minutes after salbutamol administration third PFT . Patients must demonstrate an increase in FEV1 of at least 12 and 200 mL from the pre-dose PFT to the second PFT or from the pre-dose PFT to the third PFT. 9.Patients must be able to perform technically acceptable pulmonary function tests and Peak flow measurements with the electronic peak flow meter and must be able to perform all necessary recordings in the electronic diary as part of the electronic peak flow meter Asthma Monitor . 10.Patients must be able to inhale medication in a competent manner from the Respimat inhaler and from a metered dose inhaler MDI . |
|
E.4 | Principal exclusion criteria |
1.Patients with a significant disease other than asthma. 2.Patients with recent history i.e., six months or less of myocardial infarction 3.Patients who have been hospitalized for heart failure NYHA class III or IV within the past year 4.Patients with any unstable or life threatening cardiac arrhythmia or cardiac arrhythmia requiring intervention or a change in drug therapy within the past year 5.Patients with malignancy for which the patient has undergone resection, radiation therapy or chemotherapy within the last five years. Patients with treated basal cell carcinoma are allowed. 6.Patients with a diagnosis of chronic obstructive pulmonary disease COPD 7.Patients with a history of life threatening pulmonary obstruction, or a history of cystic fibrosis or clinically evident bronchiectasis 8.Patients with known active tuberculosis 9.Patients who have undergone thoracotomy with pulmonary resection. Patients with a history of thoracotomy for other reasons should be evaluated as per exclusion criterion No. 1. 10.Patients who have completed a pulmonary rehabilitation program in the six weeks prior to visit 1 or patients who are currently in a pulmonary rehabilitation program that will not be maintained throughout the duration of the study. 11.Patients who are being treated with beta-blocker medication. Cardio-selective beta-blocker eye medication for treatment of non-narrow angle glaucoma are allowed. 12.Patients who have been treated with the long-acting anticholinergic tiotropium Spiriva within 4 weeks prior to visit 1 13.Patients who were treated with cromolyn sodium or nedocromil sodium within 2 weeks prior to visit 1 14.Patients who were treated with oral betamimetics within 2 weeks prior to visit 1 15.Patients who were treated with oral corticosteroids within 4 weeks prior to visit 1 16.Patients who were treated with theophylline within 2 weeks prior to visit 1 17.Patients who were treated with leucotriene modifiers within 4 weeks prior to visit 1 18.Patients who were treated with omalizumab within 4 weeks prior to visit 1 19.Patients with known hypersensitivity to anticholinergic drugs or any other components of the inhalation solution used in the Respimat inhaler 20.Patients with known hypersensitivity to salmeterol xinafoate or any other components of the salmeterol MDI 21.Pre-menopausal women who are not surgically sterile; or are nursing or pregnant; or are of child-bearing potential and are not practicing acceptable means of birth control mechanical and/or chemical . 22.Patients who have taken an investigational drug within one month or six half lives whichever is greater prior to visit 1 23.Patients with previous participation receipt of randomised treatment in this study 24.Patients who are currently participating in another study 25.Patients with significant alcohol or drug abuse within the past two years 26.Patients with any respiratory tract infection or exacerbation in the four weeks prior to visit 1 or during the run-in period. 27.Patients requiring more than 12 puffs of rescue medication salbutamol MDI per 24 hours on 3 consecutive days during the run-in period should not be randomised |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary endpoint of this study is the change in mean weekly morning peak expiratory flow from baseline to the last week of treatment. Baseline is defined as the last week prior to randomisation visit. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | Information not present in EudraCT |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Information not present in EudraCT |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 3 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 4 |